Patents by Inventor Larisa Poluektova

Larisa Poluektova has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Non-human animal having human IL-34 and use Thereof
    Patent number: 11419317
    Abstract: The present invention provides a non-human animal having human interleukin-34 (IL-34) in the body thereof; a method for producing a non-human animal having human microglia, which includes transplanting human CD34-positive hematopoietic stem cells into the non-human animal having human IL-34 in the body; and a method for producing human microglia, which includes obtaining human microglia from the non-human animal having human microglia.
    Type: Grant
    Filed: March 18, 2019
    Date of Patent: August 23, 2022
    Assignees: Central Institute for Experimental Animals
    Inventors: Larisa Poluektova, Santhi Gorantla, Mamoru Ito, Ikumi Katano
  • NON-HUMAN ANIMAL HAVING HUMAN IL-34 AND USE THEREOF
    Publication number: 20210352877
    Abstract: The present invention provides a non-human animal having human interleukin-34 (IL-34) in the body thereof; a method for producing a non-human animal having human microglia, which includes transplanting human CD34-positive hematopoietic stem cells into the non-human animal having human IL-34 in the body; and a method for producing human microglia, which includes obtaining human microglia from the non-human animal having human microglia.
    Type: Application
    Filed: March 18, 2019
    Publication date: November 18, 2021
    Inventors: Larisa Poluektova, Santhi Gorantla, Mamoru Ito, Ikumi Katano
  • Immunomodulating active substance
    Patent number: 5731357
    Abstract: The invention is an immunomodulator-antistressant and allows to protect immune system from depressive influence of chronic emotional stress with this preventing depression in 1.25-2.5 times of immune reaction. It intensifies humoral immune reaction in 1.9-2.3 times and stimulates phagocyte activity of macrophages in 1.3-1.85 times which is especially important for treatment of immunodeficiency states.With the presence of pathological increased immune reaction (autoimmune diseases--rheumatic arthritis, non-specific ulcerative colitis, psoriasis, chronic glomerulonephritis, etc.) it normalises it, suppressing the progress of humoral immune reaction in 4.7-11.8 times.
    Type: Grant
    Filed: January 18, 1996
    Date of Patent: March 24, 1998
    Inventors: Juris Rubens, Larisa Poluektova, Nadezda Gromova, Jurijs Seleznovs